Novo Nordisk on Thursday launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera , after Pfizer in ...

The Danish pharma was rumored to be a bidder in the process to acquire Metsera earlier this year, which Pfizer ultimately won ...

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential ...

In a stunning twist, Novo Nordisk blindsides Pfizer in the obesity drug race--sparking one of pharma's boldest takeover ...

While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Pfizer says Novo Nordisk bid breaks law, calling the $9B Metsera offer an illegal attempt to eliminate a U.S. competitor with antitrust risks.

Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...

Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...